Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy

Cancer Biology and Therapy

Volumn 12, Issue 9, 2011, Pages 827-836

  Inoue, Hiromi ^a,b   Hwang, Sung Hee ^b   Wecksler, Aaron T ^b   Hammock, Bruce D ^b   Weiss, Robert H ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Dna damage; Kidney cancer; P21; Soluble epoxide hydrolase; Sorafenib

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 [4 (3 ADAMANTAN 1 YLUREIDO)CYCLOHEXYLOXY]BENZOIC ACID; ACTIN; DOXORUBICIN; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN TYROSINE KINASE; SORAFENIB; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CELL DEATH; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; DOXORUBICIN; DRUG SYNERGISM; HEP G2 CELLS; HUMANS; KIDNEY NEOPLASMS; MAP KINASE SIGNALING SYSTEM; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 80655129639     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.9.17680     Document Type: Article

References (54)

1. Weiss RH, Lin PY. Kidney cancer: identification of novel targets for therapy. Kidney Int 2006; 69:224-32; DOI:10.1038/sj.ki.5000065; PMID:16408110.
2. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002; 1:639-49; PMID:12479224.
3. Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003; 4:425-9; DOI:10.1016/S1535-6108(03)00308-8; PMID:14706334.
4. Weiss RH, Borowsky AD, Seligson D, Lin PY, Dillard- Telm L, Belldegrun AS, et al. p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol 2007; 177:63-8; DOI:10.1016/j.juro.2006. 08.073; PMID:17162001.
5. Winters ZE, Hunt NC, Bradburn MJ, Royds JA, Turley H, Harris AL, et al. Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer. association with prognosis. Eur J Cancer 2001; 37:2405-12; DOI:10.1016/S0959- 8049(01)00327-6;PMID:11720835.
6. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, et al. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 1999; 18:1223-34; DOI:10.1093/ emboj/18.5.1223; PMID:10064589.
7. Tanaka H, Yamashita T, Asada M, Mizutani S, Yoshikawa H, Tohyama M. Cytoplasmic p21(Cip1/ WAF1) regulates neurite remodeling by inhibiting Rho-kinase activity. J Cell Biol 2002; 158:321-9; DOI:10.1083/jcb.200202071; PMID:12119358.
8. Waf1/Cip1 increases cell cycle transit in vascular smooth muscle cells. Cell Signal 2004; 16:263-9; DOI:10.1016/S0898-6568(03)00136-0; PMID:14636896.
9. Biankin AV, Kench JG, Morey AL, Lee CS, Biankin SA, Head DR, et al. Overexpression of p21(WAF1/ CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res 2001; 61:8830-7; PMID:11751405.
10. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-34; DOI:10.1056/NEJMoa060655; PMID:17215530.
11. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69:223-40; DOI:10.2165/00003495-200969020- 00006; PMID:19228077.
12. Newman JW, Morisseau C, Hammock BD. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res 2005; 44:1-51; DOI:10.1016/j.plipres.2004.10.001; PMID:15748653.
13. Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ. Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat 2007; 82:50-9; DOI:10.1016/j.prostaglandins.2006.05.017;PMID:17164132.
14. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 2002; 39:690-4; DOI:10.1161/hy0202.103788; PMID:11882632.
15. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 2004; 15:1244-53; PMID:15100364.
16. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 2005; 46:975-81; DOI:10.1161/01. HYP.0000176237.74820.75; PMID:16157792.
17. Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, Hammock BD, et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005; 45:759-65; DOI:10.1161/01. HYP.0000153792. 29478.1d; PMID:15699457.
18. Schmelzer KR, Inceoglu B, Kubala L, Kim IH, Jinks SL, Eiserich JP, et al. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 2006; 103:13646-51; DOI:10.1073/pnas.0605908103; PMID:16950874.
19. Ulu A, Davis BB, Tsai HJ, Kim IH, Morisseau C, Inceoglu B, et al. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol 2008; 52:314-23; DOI:10.1097/ FJC.0b013e318185fa3c; PMID:18791465.
20. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 2005; 102:9772-7; DOI:10.1073/pnas.0503279102; PMID:15994227.
21. Liu JY, Park SH, Morisseau C, Hwang SH, Hammock BD, Weiss RH. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Mol Cancer Ther 2009; 8:2193-203; DOI:10.1158/1535-7163. MCT-09-0119; PMID:19671760.
22. Lin PY, Fosmire SP, Park SH, Park JY, Baksh S, Modiano JF, et al. Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: A potential mechanism of apoptosis resistance. Mol Cancer 2007; 6:16; DOI:10.1186/1476-4598-6-16; PMID:17300726.
23. Park SH, Park JY, Weiss RH. Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53. J Urol 2008; 180:352-60; DOI:10.1016/j.juro.2008.02.038;PMID:18499163.
24. Liu XF, Xia YF, Li MZ, Wang HM, He YX, Zheng ML, et al. The effect of p21 antisense oligodeoxynucleotides on the radiosensitivity of nasopharyngeal carcinoma cells with normal p53 function. Cell Biol Int 2006; 30:283-7; DOI:10.1016/j.cellbi.2005.11.010;PMID:16448826.
25. Fan Y, Borowsky AD, Weiss RH. An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells. Mol Cancer Ther 2003; 2:773-82; PMID:12939467.
26. WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res 2000; 60:679-84; PMID:10676653.
27. WAF1/CIP1 sensitizes human breast cancer cells to paclitaxel and its combination with 5-fluorouracil. Anticancer Res 2002; 22:3197-204; PMID:12530065.
28. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de VD, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92:1855-61; DOI:10.1038/sj.bjc.6602584; PMID:15870716.
29. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23:965-72; DOI:10.1200/JCO.2005.06.124; PMID:15613696.
30. Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 2008; 99:1492-8; DOI:10.1111/j.1349-7006.2008.00837.x; PMID:18477034.
31. Cip1/ WAF1 and promotes cell survival. J Biol Chem 2002; 277:11352-61; DOI:10.1074/jbc. M109062200; PMID:11756412.
32. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7:85-90; DOI:10.1038/ng0594-85; PMID:7915601.
33. Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998; 22:200-9; DOI:10.1002/(SICI)1098- 2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#;PMID: 9624531.
34. Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner RD. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 2002; 62:3014-9; PMID:12036906.
35. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006; 22:395-405; DOI:10.1016/j.molcel.2006.04.006; PMID:16678111.
36. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006; 24:5601-8; DOI:10.1200/JCO.2006.08.5415; PMID:17158546.
37. Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 2007; 50:3825-40; DOI:10.1021/jm070270t; PMID:17616115.
38. Lee S, Baek M, Kim H, Ha J, Jeoung D. Mechanism of doxorubicin-induced cell death and expression profile analysis. Biotechnol Lett 2002; 24:1147-51; DOI:10.1023/A:1016174800956.
39. Branham MT, Nadin SB, Vargas-Roig LM, Ciocca DR. DNA damage induced by paclitaxel and DNA repair capability of peripheral blood lymphocytes as evaluated by the alkaline comet assay. Mutat Res 2004; 560:11-7; PMID:15099819.
40. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005; 5:231-7; DOI:10.1038/nrc1560; PMID:15738985.
41. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411:342-8; DOI:10.1038/35077213; PMID:11357141.
42. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55:5187-90; PMID:7585571.
43. Park SH, Wang X, Liu R, Lam KS, Weiss RH. High throughput screening of a small molecule one-beadone- compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers. Cancer Biol Ther 2008; 7:2015-22; DOI:10.4161/cbt.7.12.7069; PMID:18981726.
44. Sharma RR, Ravikumar TS, Raimo D, Yang WL. Induction of p21(WAF1) expression protects HT29 colon cancer cells from apoptosis induced by cryoinjury. Ann Surg Oncol 2005; 12:743-52; PMID:16078010.
45. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21 [see comments]. Nature 1996; 381:713-6; DOI:10.1038/381713a0; PMID:8649519.
46. waf1 in human malignant mesothelioma. Clin Cancer Res 2008; 14:5099-107; DOI:10.1158/1078- 0432.CCR-08-0255; PMID:18698027.
47. Linehan WM, Zbar B. Focus on kidney cancer. Cancer Cell 2004; 6:223-8; DOI:10.1016/j.ccr.2004.09.006; PMID:15380513.
48. Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene 1999; 18:1131-8; DOI:10.1038/sj.onc.1202426; PMID:10022118.
49. Sohn D, Essmann F, Schulze-Osthoff K, Janicke RU. p21 blocks irradiation-induced apoptosis downstream of mitochondria by inhibition of cyclin-dependent kinase-mediated caspase-9 activation. Cancer Res 2006; 66:11254-62; DOI:10.1158/0008-5472.CAN-06-1569; PMID:17145870.
50. Tang JJ, Shen C, Lu YJ. Requirement for pre-existing of p21 to prevent doxorubicin-induced apoptosis through inhibition of caspase-3 activation. Mol Cell Biochem 2006; 291:139-44; DOI:10.1007/s11010-006-9206-7; PMID:16909308.
51. Kim D, Cheng GZ, Lindsley CW, Yang H, Cheng JQ. Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. Curr Opin Investig Drugs 2005; 6:1250-8; PMID:16370391.
52. Tomasello L, Sertoli MR, Rubagotti A, Guglielmini P, Tacchini L, Bedognetti D, et al. Combination of sorafenib and weekly gemcitabine in patients (pts) with metastatic renal cell Cancer (MRCC): A phase II study, preliminary results. J Clin Oncol 2008; 26.
53. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, et al. Doxorubicin plus sorafenib vs. doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304:2154-60; DOI:10.1001/jama.2010.1672; PMID:21081728.
54. Heim M, Scharifi M, Zisowsky J, Jaehde U, Voliotis D, Seeber S, et al. The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs 2005; 16:129-36; DOI:10.1097/00001813-200502000-00003; PMID:15655409.